Abstract
Thrombin activatable fibrinolysis inhibitor (TAFI) is a zymogene that potently inhibits fibrinolysis through the removal of the carboxy-terminal lysine and arginine residues from partially degraded fibrin polymers. In addition, TAFI has a suppressor effect on conversion of inactive plasminogen to plasmin. Since impaired fibrinolysis is a very well established risk factor for cardiovascular morbidity and mortality, understanding the role of TAFI in cardiovascular disorders, insulin resistance, diabetes and other endocrine problems may hold promise for improving management of these diseases. This paper includes a review of current evidence on TAFI pathway and its alteration in endocrine and cardiovascular disorders and relevant patents.
Keywords: Coronary artery disease, diabetes, estrogen, stroke, TAFI, thyroid dysfunction.
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery
Title:Role of Thrombin Activatable Fibrinolysis Inhibitor in Endocrine and Cardiovascular Disorders: An Update
Volume: 6 Issue: 3
Author(s): Baris Akinci
Affiliation:
Keywords: Coronary artery disease, diabetes, estrogen, stroke, TAFI, thyroid dysfunction.
Abstract: Thrombin activatable fibrinolysis inhibitor (TAFI) is a zymogene that potently inhibits fibrinolysis through the removal of the carboxy-terminal lysine and arginine residues from partially degraded fibrin polymers. In addition, TAFI has a suppressor effect on conversion of inactive plasminogen to plasmin. Since impaired fibrinolysis is a very well established risk factor for cardiovascular morbidity and mortality, understanding the role of TAFI in cardiovascular disorders, insulin resistance, diabetes and other endocrine problems may hold promise for improving management of these diseases. This paper includes a review of current evidence on TAFI pathway and its alteration in endocrine and cardiovascular disorders and relevant patents.
Export Options
About this article
Cite this article as:
Akinci Baris, Role of Thrombin Activatable Fibrinolysis Inhibitor in Endocrine and Cardiovascular Disorders: An Update, Recent Patents on Endocrine, Metabolic & Immune Drug Discovery 2012; 6 (3) . https://dx.doi.org/10.2174/187221412802481748
DOI https://dx.doi.org/10.2174/187221412802481748 |
Print ISSN 1872-2148 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3334 |
Related Articles
-
A Glance Over the Cannabinoid Machinery to Design New Anti- Angiogenic Compounds
Mini-Reviews in Medicinal Chemistry Small-Molecules Targeting Kinases Involved in Pulmonary Hypertension: a Patent Review (2010-2015)
Current Medicinal Chemistry Impact of Drug Metabolism/Pharmacokinetics and their Relevance Upon Traditional Medicine-based Cardiovascular Drug Research
Current Drug Metabolism 3, 5-Diiodothyronine: Biological Actions and Therapeutic Perspectives
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Recombinant Activated Factor VII as a General Haemostatic Agent:Evidence-Based Efficacy and Safety
Current Drug Safety Inflammatory Arthritis and Heart Disease
Current Pharmaceutical Design Pharmacoproteomics in Cardiac Hypertrophy and Atherosclerosis
Cardiovascular & Hematological Disorders-Drug Targets Physiological and Comparative Evidence Fails to Confirm an Adaptive Role for Aging in Evolution
Current Aging Science The Ultrasonographic Diagnosis of Polycystic Ovary Syndrome
Current Medical Imaging Recent Developments on Coronary Microvasculopathy after Heart Transplantation:A New Target in the Therapy of Cardiac Allograft Vasculopathy
Current Vascular Pharmacology The cAMP-Dependent Protein Kinase Pathway as Therapeutic Target – Possibilities and Pitfalls
Current Topics in Medicinal Chemistry PPARγ Agonists: Beneficial Effect on Blood Pressure Beyond Glycemic Control?
Current Hypertension Reviews Mutations of Nuclear and Mitochondrial Genomes as Potential Targets for the Treatment of Metabolic Syndrome
Current Pharmaceutical Design Ex Vivo Gene Transfer for Improvement of Transplanted Pancreatic Islet Viability and Function
Current Pharmaceutical Design C-Reactive Protein: Interaction with the Vascular Endothelium and Possible Role in Human Atherosclerosis
Current Pharmaceutical Design Changes in Serum Markers of Inflammation and Endothelial Activation in HIV-Infected Antiretroviral Naive Patients Starting A Treatment with Abacavir-Lamivudine or Tenofovir-Emtricitabine Plus Efavirenz
Current HIV Research Effects of Nutrients on Postprandial Lipemia
Current Vascular Pharmacology Cardioprotective Effects of the Polyphenol Hydroxytyrosol from Olive Oil
Current Drug Targets Novel Molecular Targets in the Treatment of Cardiac Hypertrophy
Recent Patents on Cardiovascular Drug Discovery A Systematic Approach to Hypertensive Urgencies and Emergencies
Current Hypertension Reviews